HF
MYGN icon

HRT Financial’s Myriad Genetics MYGN Stock Holding History

HRT Financial’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.04M Buy
1,786,319
+1,317,451
+281% +$6.86M 0.02% 722
2025
Q4 		$2.88M Sell
468,868
-321,701
-41% -$2.33M 0.01% 1070
2025
Q3 		$5.71M Buy
790,569
+650,669
+465% +$3.86M 0.02% 629
2025
Q2 		$742K Buy
+139,900
New +$826K ﹤0.01% 1414
2024
Q4 		– Sell
-22,193
Closed -$607K – 2949
2024
Q3 		$607K Buy
+22,193
New +$601K ﹤0.01% 1499
2023
Q4 		– Sell
-70,472
Closed -$1.13M – 2816
2023
Q3 		$1.13M Buy
+70,472
New +$1.34M 0.01% 900
2023
Q2 		– Sell
-103,309
Closed -$2.4M – 2976
2023
Q1 		$2.4M Buy
103,309
+65,916
+176% +$1.34M 0.03% 507
2022
Q4 		$542K Buy
+37,393
New +$697K 0.01% 1354
2022
Q2 		– Sell
-41,813
Closed -$1.05M – 3431
2022
Q1 		$1.05M Buy
+41,813
New +$1.07M 0.01% 984
2021
Q1 		– Sell
-28,227
Closed -$558K – 2992
2020
Q4 		$558K Sell
28,227
-10,797
-28% -$174K 0.01% 970
2020
Q3 		$508K Buy
+39,024
New +$494K 0.01% 868

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HRT Financial's MYGN Position: Q1 2026 in Review

HRT Financial increased its Myriad Genetics (MYGN) stake by 281% in Q1 2026, buying an estimated $6.86M and bringing the position to 1,786,319 shares worth $8.04M. The position accounts for 0.02% of the portfolio, ranked #722.

HRT Financial first reported a position in MYGN in Q3 2020 and has held it in 11 quarters since. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • HRT Financial held 1,786,319 shares of Myriad Genetics worth $8.04M as of Q1 2026.
  • HRT Financial bought 1,317,451 Myriad Genetics shares in Q1 2026, an estimated $6.86M.
  • Myriad Genetics made up 0.02% of HRT Financial's portfolio in Q1 2026, its #722 holding.
  • HRT Financial first reported a position in Myriad Genetics in Q3 2020 and has held it in 11 quarters since.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.